Kinetics and Potency of GD2 CAR-T Cell-Mediated Cytolysis of Glioblastoma

Heather Hayes[1], Meghan Logun[2], Stacie Chvatal[1], Katie Mueller[3], Nicole Piscopo[3], Amritava Das[3], Krishanu Saha[3], Daniel Millard[1], and Lohitash Karumbaiah[2]

[1]Axion BioSystems, Atlanta, GA, USA, [2]University of Georgia, Regenerative Biosciences, Athens, GA, USA, [3]University of Wisconsin-Madison, Madison, WI, USA

AXION BIOSYSTEMS
Imagine • Explore • Discover

Maestro Z: Dynamic Cell Tracking

Impedance Technology

Glioblastoma (GBM) is an aggressive form of brain cancer that has no effective treatments and a prognosis of only 12-15 months. Immune effector T cells are a promising therapy due to their innate cytotoxicity. In addition, engineering chimeric antigen receptors (CAR) to target tumor-associated or neo-antigens can lend high specificity. Assessing the efficacy and potency of such T cell therapies label-free, *in vitro*, and at high throughputs is vital for the preclinical development of these promising therapies.

Axion BioSystems' Maestro Z platform offers impedance-based cell analysis for real-time, label-free monitoring of cell viability, morphology, cytolysis, and signaling. Here, we present a characterization of GD2 targeted CAR-T cell mediated killing of glioma stem cells, a subpopulation of glioblastoma cells, using the Maestro Z.



The impedance is measured from electrodes embedded in the bottom of each well. As cells cover more of the electrode, impedance increases in proportion to the number of viable cells. If a perturbation kills the attached cells, impedance decreases.

The Maestro Z Platform



- **Label-free, non-invasive tracking** of cultured cells
- **Integrated environmental control** provides a stable environment for short- and long-term studies with a small benchtop footprint
- **Automatic and continuous cell monitoring** from 96 or 384 wells simultaneously
- **"One button setup"** automatically docks the plate and adjusts temperature and CO_2 levels
- **Powerful data analysis** to focus on the science, while AxIS Z handles the details with simple setup and automatic experiment tracking
- **See your cells** with the viewing window included in each well of the CytoView-Z 96-well plate
- **State-of-the-art electrode processing chip (BioCore v4)** enables advanced endpoints, such as barrier index, to further characterize cell-based models

Impedance Assay is Directly Correlated with Cell Viability

To validate impedance-based monitoring of cell viability, Calu-3 cells were added to a CytoView-Z plate with varying number of cells per well and monitored for four hours on the Maestro Z platform. The change in resistance was correlated with the number of cells initially seeded, and the resistance continued to increase as the cells adhered and flattened on the surface. At four hours post-seeding, the plate was removed and an MTT assay was performed in the CytoView-Z plate. The resistance measured with the Maestro Z platform was linear with respect to cell number and directly correlated to the MTT assay readings from the same wells.



Dynamic Cytotoxicity Assay

Impedance Assay Measures Diverse Cell Properties

The Maestro Z records impedance at multiple frequencies simultaneously, enabling a thorough characterization of cell behavior, including:

- **Coverage** – the change in impedance is directly related to the number of cells covering the electrode.
- **Cytotoxicity** – dynamic monitoring of cell viability provides measures of the degree and speed of cell death.
- **Morphology** – cell size, shape, and intercellular tight junctions significantly impact the measured impedance.
- **Signaling** – small changes in cell shape or cytoskeleton organization are detected in response to intracellular signaling events



GD2 as a CAR-T Target for Glioblastoma

Patient-derived N08 Glioma Stem Cells (GSCs) have high expression of CAR-T target antigen GD2 compared to other popular CAR-T targets for solid tumors as seen in imaging flow cytometry (A). This was further seen in MFI values taken from the same samples, showing that GD2 expression on N08 GSCs is significantly higher than other CAR-T target antigen expression (B). High GD2+ expression is retained in rodent xenograft tumors inoculated using N08 GSCs (C, top). GD2 is also abundantly expressed in human GBM patient samples as seen in human patient tissue arrays compared to healthy control tissue (C, bottom).



Continuous Monitoring of Glioma Stem Cell Viability

As the changes in impedance are correlated with cell attachment and viability, continuous, label-free monitoring with the Maestro Z can be used to track the kinetics of cytotoxicity over time. Patient-derived N08 glioma stem cells (GSCs) were plated at 50k cells per well on CytoView-Z 96-well plates, and their impedance was continuously monitored on the Maestro Z. After 48 hrs, GD2 targeted CAR-T cells were added at Effector:Target (E:T) ratios ranging from 0.1:1 up to 10:1. Impedance and cytolysis were subsequently monitored for up to 7 days. In addition, some wells were left untreated (GSC, teal) to serve as a No Treatment Control, while others received 50k CAR-T cells alone (pink).



As expected, non-adherent CAR-T cells alone (pink) showed little change in impedance as they do not attach to the surface. Untreated GSCs (teal) continued to exhibit an impedance of ~ 20 Ohms. All ratios of GD2 CAR-T cells induced a decrease in impedance reflecting significant GSC cell death (green, purple, blue). Higher ratios of GD2 CAR-T cells induced an initial increase in impedance, likely reflective of cell swelling or inflammation, before a subsequent decrease in impedance. To the right, impedance at ~ 6 days post-addition is shown across groups.

Immune Cell-Mediated Cytotoxicity

Kinetics and Potency of GD2 CAR-T Cells against GSCs

Impedance is valuable for evaluating both the potency and efficiency of immune cell-mediated cytotoxicity.

Here, percent cytolysis was used to compare the potency of targeted, retroviral (RV) transduced GD2 CAR-T cells to untargeted naïve activated T cells (H24FW). Percent cytolysis was computed by comparing T cell or CAR-T cell treated wells to untreated GSC wells (No Treatment Control, 0% Cytolysis) and wells with effector cells only (100% Cytolysis). Kill Time 50 was defined as time after dosing required to reach 50% cell death.



GD2 CAR-T cells exhibited greater potency for killing GSCs, as seen in a higher final percent cytolysis. All Effector:Target ratios of GD2 CAR-T cells induced > 50% cytolysis on average over 7 days. While the final percent cytolysis did not differ across ratios, the highest ratio exhibited delayed cytolysis likely due to the large initial swelling or inflammatory response.



GD2 CAR-T Cells Exhibit Markers of Activation and Early Exhaustion from Antigen Exposure

CAR-T cell state was evaluated with flow cytometry at day 2 and day 7. After 7 days in co-culture, GD2 CAR-T cells exhibited markers of chronic activation, including high CD69+ and increasing CD137+ over time. Early exhaustion of GD2 CAR-T cells was suggested by expression of PD1 (80% of cells) and LAG3 (35% of cells), but not TIM3.



Conclusions

- GD2 CAR-T cells exhibited greater potency against patient-derived glioblastoma compared to naïve activated T cells, suggesting greater clinical potential.
- Dynamic cell tracking allowed quantification of the kinetics of immune-cell mediated cytolysis, including kill time 50, across doses. While the final cytolysis did not differ across ratios, the kinetic profile differed, highlighting the importance of continuous monitoring over the course of cytolysis.
- Overall, the Maestro Z platform enabled continuous, dynamic, label-free quantification of the potency, efficiency, and kinetics of immune-cell mediated cytolysis of glioblastoma.

Acknowledgements

- We would like to thank our funding sources, American Brain Tumor Association (ABTA, discovery grant) and the NSF Engineering research center (ERC) for cell manufacturing therapies (NSF-EEC 1648035). We also thank Dr. Daniel J Brat from the Northwestern Feinberg School of Medicine who generously gifted us the patient-derived glioblastoma stem cells.